{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-24-000047","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.312700+00:00","generated_at":"2026-06-01T09:03:11.122213+00:00","sec_items":["3.03","5.03","5.02","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Curis cuts workforce ~30%, focuses on combo studies; cash runway into 2025","bullets":["Board approved ~30% workforce reduction as monotherapy trials near completion.","Company focusing on combination studies in CNS lymphoma and front-line AML.","Expects no significant 2024 cost impact; cost reductions anticipated in 2025.","Stockholders approved increasing authorized common shares to 34,171,875.","Stockholders approved additional 942,100 shares for 2010 Stock Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-24-000047","json":"https://secwatch.observer/filing/0001108205-24-000047.json","markdown":"https://secwatch.observer/filing/0001108205-24-000047.md","text":"https://secwatch.observer/filing/0001108205-24-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000047/0001108205-24-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000047/cris-20240521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:03:11.122213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}